Patent · US Active

Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein

US8715694B2 · kind B2 · utility

50Cited by
13References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 16, 2012
Grant dateMay 6, 2014
Priority date
Expiry dateApr 16, 2032

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides polypeptides and virus-like particles having, for example, an ability to induce an immune response to flaviviruses. The polypeptides can include C15, prM, and E polypeptide sequences.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.